fda compounding semaglutide news today 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" FDA Moves to Restrict Mass-Marketed

10.1161/HYPERTENSIONAHA.120.1654733356394 113 Wang L, Mesa-Eguiagaray I, Campbell H, et al

More study is needed to determine the full therapeutic potential of GLP-1RAs and understand the mechanisms behind their anti-inflammatory effects

Without it, you are trusting that an unregulated overseas lab correctly synthesized one of the most complex peptide drugs on the market

Click here to find head-to-head results

PubMed, den Heijer, M., et al

Of course, we have no experience on how people with immune-related or inflammatory disease or individuals, who are also taking immunosuppressive agents, will fare with long term GLP-1 use, and this must be studied. In this sense, the classs history of use over the past 20 years could be a great asset, according to Wright